Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
ln Vivo |
A novel Ca2+ channel antagonist for spontaneously hypertensive rats is aranidipine (MPC-1304). Upon administering oral doses of 3 and 10 mg/kg of aradipine to spontaneously hypertensive rats (SHR), there was a significant increase in the Bmax value of specific [3H](+)-PN 200-110 binding to the myocardium in comparison to the control group. to reduce the values. In comparison to the control values, the Bmax values at 1 hour (3 mg/kg), 1 hour, and 6 hours (10 mg/kg) were significantly lower (47.7%, 48.9%, and 25.8%, respectively). The effect peaks after an hour and gradually wanes. The Bmax values following oral administration of alandipine at 6 hours (3 mg/kg) and 12 or 24 hours (10 mg/kg) did not show a significant difference from the control values, suggesting that the alandipine effect was no longer present. The myocardial [3H](+)-PN 200-110 binding's Kd value is unaffected by alandipine taken orally [1].
|
---|---|
References |
[1]. Nozawa Y, et al. Receptor occupation and pharmacokinetics of MPC-1304, a new Ca2+ channel antagonist, in spontaneously hypertensive rats. Eur J Pharmacol. 1995 Dec 12;287(2):191-6
|
Molecular Formula |
C19H20N2O7
|
---|---|
Molecular Weight |
388.38
|
Exact Mass |
388.1271
|
CAS # |
86780-90-7
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C(C1=C(C)NC(C)=C(C(OCC(C)=O)=O)C1C2=CC=CC=C2[N+]([O-])=O)OC
|
Synonyms |
Aranidipine MPC 1304 MPC-1304 MPC1304CCRIS 6724 CCRIS-6724 CCRIS6724
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~125 mg/mL (~321.86 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5748 mL | 12.8740 mL | 25.7480 mL | |
5 mM | 0.5150 mL | 2.5748 mL | 5.1496 mL | |
10 mM | 0.2575 mL | 1.2874 mL | 2.5748 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.